These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
134 related articles for article (PubMed ID: 35325211)
1. Phase I Study of JNJ-74699157 in Patients with Advanced Solid Tumors Harboring the KRAS G12C Mutation. Wang J; Martin-Romano P; Cassier P; Johnson M; Haura E; Lenox L; Guo Y; Bandyopadhyay N; Russell M; Shearin E; Lauring J; Dahan L Oncologist; 2022 Jul; 27(7):536-e553. PubMed ID: 35325211 [TBL] [Abstract][Full Text] [Related]
2. First-in-Human Phase I/IB Dose-Finding Study of Adagrasib (MRTX849) in Patients With Advanced Ou SI; Jänne PA; Leal TA; Rybkin II; Sabari JK; Barve MA; Bazhenova L; Johnson ML; Velastegui KL; Cilliers C; Christensen JG; Yan X; Chao RC; Papadopoulos KP J Clin Oncol; 2022 Aug; 40(23):2530-2538. PubMed ID: 35167329 [TBL] [Abstract][Full Text] [Related]
3. KRAS Hong DS; Fakih MG; Strickler JH; Desai J; Durm GA; Shapiro GI; Falchook GS; Price TJ; Sacher A; Denlinger CS; Bang YJ; Dy GK; Krauss JC; Kuboki Y; Kuo JC; Coveler AL; Park K; Kim TW; Barlesi F; Munster PN; Ramalingam SS; Burns TF; Meric-Bernstam F; Henary H; Ngang J; Ngarmchamnanrith G; Kim J; Houk BE; Canon J; Lipford JR; Friberg G; Lito P; Govindan R; Li BT N Engl J Med; 2020 Sep; 383(13):1207-1217. PubMed ID: 32955176 [TBL] [Abstract][Full Text] [Related]
4. Adagrasib in Advanced Solid Tumors Harboring a Bekaii-Saab TS; Yaeger R; Spira AI; Pelster MS; Sabari JK; Hafez N; Barve M; Velastegui K; Yan X; Shetty A; Der-Torossian H; Pant S J Clin Oncol; 2023 Sep; 41(25):4097-4106. PubMed ID: 37099736 [TBL] [Abstract][Full Text] [Related]
5. Single-Agent Divarasib (GDC-6036) in Solid Tumors with a Sacher A; LoRusso P; Patel MR; Miller WH; Garralda E; Forster MD; Santoro A; Falcon A; Kim TW; Paz-Ares L; Bowyer S; de Miguel M; Han SW; Krebs MG; Lee JS; Cheng ML; Arbour K; Massarelli E; Choi Y; Shi Z; Mandlekar S; Lin MT; Royer-Joo S; Chang J; Dharia NV; Schutzman JL; Desai J; N Engl J Med; 2023 Aug; 389(8):710-721. PubMed ID: 37611121 [TBL] [Abstract][Full Text] [Related]
6. Adagrasib in Non-Small-Cell Lung Cancer Harboring a Jänne PA; Riely GJ; Gadgeel SM; Heist RS; Ou SI; Pacheco JM; Johnson ML; Sabari JK; Leventakos K; Yau E; Bazhenova L; Negrao MV; Pennell NA; Zhang J; Anderes K; Der-Torossian H; Kheoh T; Velastegui K; Yan X; Christensen JG; Chao RC; Spira AI N Engl J Med; 2022 Jul; 387(2):120-131. PubMed ID: 35658005 [TBL] [Abstract][Full Text] [Related]
7. D-1553 (Garsorasib), a Potent and Selective Inhibitor of KRAS Li Z; Song Z; Zhao Y; Wang P; Jiang L; Gong Y; Zhou J; Jian H; Dong X; Zhuang W; Cang S; Yang N; Fang J; Shi J; Lu J; Ma R; Wu P; Zhang Y; Song M; Xu CW; Shi Z; Zhang L; Wang Y; Wang X; Zhang Y; Lu S J Thorac Oncol; 2023 Jul; 18(7):940-951. PubMed ID: 36948246 [TBL] [Abstract][Full Text] [Related]
10. Sotorasib in Strickler JH; Satake H; George TJ; Yaeger R; Hollebecque A; Garrido-Laguna I; Schuler M; Burns TF; Coveler AL; Falchook GS; Vincent M; Sunakawa Y; Dahan L; Bajor D; Rha SY; Lemech C; Juric D; Rehn M; Ngarmchamnanrith G; Jafarinasabian P; Tran Q; Hong DS N Engl J Med; 2023 Jan; 388(1):33-43. PubMed ID: 36546651 [TBL] [Abstract][Full Text] [Related]
11. Sotorasib for previously treated colorectal cancers with KRAS Fakih MG; Kopetz S; Kuboki Y; Kim TW; Munster PN; Krauss JC; Falchook GS; Han SW; Heinemann V; Muro K; Strickler JH; Hong DS; Denlinger CS; Girotto G; Lee MA; Henary H; Tran Q; Park JK; Ngarmchamnanrith G; Prenen H; Price TJ Lancet Oncol; 2022 Jan; 23(1):115-124. PubMed ID: 34919824 [TBL] [Abstract][Full Text] [Related]
12. Sotorasib: a treatment for non-small cell lung cancer with the KRAS G12C mutation. Zheng X; Luo J; Liu W; Ashby CR; Chen ZS; Lin L Drugs Today (Barc); 2022 Apr; 58(4):175-185. PubMed ID: 35412531 [TBL] [Abstract][Full Text] [Related]
13. FDA Approval Summary: Sotorasib for KRAS G12C-Mutated Metastatic NSCLC. Nakajima EC; Drezner N; Li X; Mishra-Kalyani PS; Liu Y; Zhao H; Bi Y; Liu J; Rahman A; Wearne E; Ojofeitimi I; Hotaki LT; Spillman D; Pazdur R; Beaver JA; Singh H Clin Cancer Res; 2022 Apr; 28(8):1482-1486. PubMed ID: 34903582 [TBL] [Abstract][Full Text] [Related]
14. Concomitant KRAS mutations attenuate sensitivity of non-small cell lung cancer cells to KRAS G12C inhibition. Vaclova T; Chakraborty A; Sherwood J; Ross S; Carroll D; Barrett JC; Downward J; de Bruin EC Sci Rep; 2022 Feb; 12(1):2699. PubMed ID: 35177674 [TBL] [Abstract][Full Text] [Related]
15. Targeting KRAS in Colorectal Cancer. Wang C; Fakih M Curr Oncol Rep; 2021 Feb; 23(3):28. PubMed ID: 33582927 [TBL] [Abstract][Full Text] [Related]
17. The dominant role of G12C over other KRAS mutation types in the negative prediction of efficacy of epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer. Fiala O; Pesek M; Finek J; Benesova L; Belsanova B; Minarik M Cancer Genet; 2013; 206(1-2):26-31. PubMed ID: 23313110 [TBL] [Abstract][Full Text] [Related]